Belfast Health and Social Care Trust
caring supporting improving together

FOI/38586

5 November 2026

Number Of Patients Treated With Specific Medicines For The Treatment Of Lower GI Cancer and Cemiplimab

Q1. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 12 months between 1st October 2025 and the end of September 2026, or latest 12-months for which data are available.

Therapy Area	ICD-10 codes	Number patients
1.1 Colorectal Cancer	C18*, C19*, C20*	*14
1.2 Colon Cancer	C18*	

*refers solely to patients with a new diagnosis, where SACT was their first definitive treatment, and treatment started between 1 October 2025 and the end of September 2026. Belfast Trust does not hold information in a format that differentiates between colon cancer and colorectal cancer.

Q2. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available.

Therapy Area	ICD-10 codes	Number patients
2.1 Colorectal Cancer	C18*, C19*, C20*	*14
2.2 Colon Cancer	C18*	

*refers solely to patients with a new diagnosis, where SACT was their first definitive treatment, and treatment started between 1 July 2026 and the end of September 2026. Belfast Trust does not hold information in a format that differentiates between colon cancer and colorectal cancer.

Q3. How many patients with the following types of cancer were treated with surgical resection in the past 3 months from 1st July 2026 to the end of September 2026?

5 November 2026

Therapy Area	ICD-10 codes	Number patients treated with Surgical resection
3.1 Colorectal Cancer	C18*, C19*, C20*	38
3.2 Colon Cancer	C18*	

Belfast Trust does not hold information in a format that differentiates between colon cancer and colorectal cancer.

Q4. How many patients with the following types of cancer received SACT therapy as Adjuvant treatment in the past 3 months from 1st July 2026 to the end of September 2026?

Therapy Area	ICD-10 codes	Number patients treated with Adjuvant therapy
4.1 Colorectal Cancer	C18*, C19*, C20*	20
4.2 Colon Cancer	C18*	

Belfast Trust does not hold information in a format that differentiates between colon cancer and colorectal cancer.

Q5. How many patients with Colorectal Cancer (ICD-10 C18*, C19* & C20*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026?

Combinations as adjuvant therapy		Number patients
5.1 FOLFOX	Fluorouracil + Folinic Acid + Oxaliplatin	0
5.2 XELOX	Capecitabine + Oxaliplatin	15
5.3 FOLFIRI	Fluorouracil + Folinic Acid + Irinotecan	0
5.4 XELIRI	Capecitabine + Irinotecan	0
5.5	Nivolumab + Ipilimumab	<5

Q6. How many patients with Colon Cancer (ICD-10 C18*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026? as above – for all therapy types

5 November 2026

Combinations as adjuvant therapy		Number patients
6.1 FOLFOX	Fluorouracil + Folinic Acid + Oxaliplatin	0
6.2 XELOX	Capecitabine + Oxaliplatin	15
6.3 FOLFIRI	Fluorouracil + Folinic Acid + Irinotecan	0
6.4 XELIRI	Capecitabine + Irinotecan	0
6.5	Nivolumab + Ipilimumab	2

Belfast Health and Social Care Trust does not hold information in a format that differentiates between colon cancer and colorectal cancer. Consequently, the response to Question 6 is the same as the response provided for Question 5.

Q7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

Tumour type	Number patients treated
7.1 Cutaneous Squamous Cell Carcinoma	18
7.2 Basal Cell Carcinoma	0
7.3 Non-small Cell Lung Cancer	0
7.4 Cervical Cancer	<5

Q8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

Treatment intent	Number patients treated
8.1 Curative	0
8.2 Palliative	18

Q9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

5 November 2026

Treatment intent	Number patients treated
9.1 Adjuvant	0

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.

Under Section 1(1)(a) of the Freedom of Information Act 2000, the Trust can confirm that it does not hold information that differentiates between colon cancer and colorectal cancer.